Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

A Smart + Strong Site
Subscribe to:
Newsletters
POZ magazine
JOIN AIDSMEDS YouTube
List of Anti-HIV Meds Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
What are they?

Experimental drugs are italicized, and approved drugs are in regular, non-italicized type.

Brand Name Generic Name Abbreviation Experimental Code Pharmaceutical Company
Atripla efavirenz + tenofovir* + emtricitabine* EFV + TDF + FTC Bristol-Myers Squibb and Gilead Sciences
Complera rilpivirine + tenofovir* + emtricitabine* RPV + TDF + FTC Gilead Sciences and Janssen Therapeutics
Edurant rilpivirine RPV TMC-278 Janssen Therapeutics
Intelence etravirine ETR TMC-125 Janssen Therapeutics
Rescriptor delavirdine DLV U-90152S/T ViiV Healthcare
Sustiva efavirenz EFV DMP-266 Bristol-Myers Squibb
Viramune nevirapine NVP BI-RG-587 Boehringer Ingelheim
lersivirine UK-453061 ViiV Healthcare
* tenofovir DF and emtricitabine are nucleoside reverse transcriptase inhibitors (NRTIs)


What are Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)?

When HIV infects a CD4 cell in a person's body, it copies its own genetic code into the cell's DNA. In this way, the cell is then "programmed" to create new copies of HIV. HIV's genetic material is in the form of RNA. In order for it to infect CD4 cells, it must first convert its RNA into DNA. HIV's reverse transcriptase enzyme is needed to perform this process.

NNRTIs, also known as "non-nucleosides" or "non-nukes" for short, attach themselves to reverse transcriptase and prevent the enzyme from converting RNA to DNA. In turn, HIV's genetic material cannot be incorporated into the healthy genetic material of the cell, and prevents the cell from producing new virus.

To learn more on how HIV infects a CD4 cell and begins to create more viruses, and where each class of HIV drugs blocks this process, click on the following lesson link:

HIV Life Cycle Lesson
The HIV Life Cycle (and the targets of each class of anti-HIV drugs)


Last Revised: June 22, 2011

This content is written by the POZ and AIDSmeds editorial team. For more information, please visit our "About Us" page.


[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.